RS51294B - Inhibitorna jedinjenja za hepatitis c - Google Patents

Inhibitorna jedinjenja za hepatitis c

Info

Publication number
RS51294B
RS51294B YUP-2005/0871A YUP20050871A RS51294B RS 51294 B RS51294 B RS 51294B YU P20050871 A YUP20050871 A YU P20050871A RS 51294 B RS51294 B RS 51294B
Authority
RS
Serbia
Prior art keywords
hepatitis
inhibitor compounds
compounds
hcv
protease
Prior art date
Application number
YUP-2005/0871A
Other languages
English (en)
Serbian (sr)
Inventor
Sylvie Goulet
Jean Rancourt
Montse Llinas-Brunet
Murray D. Bailey
Punit Bhardwaj
Josée BORDELEAU
Pasquale Forgione
Elise Ghiro
Vida Gorys
Nathalie Goudreau
Teddy Halmos
Original Assignee
Boehringer Ingelheim International Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476973&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51294(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh. filed Critical Boehringer Ingelheim International Gmbh.
Publication of RS20050871A publication Critical patent/RS20050871A/sr
Publication of RS51294B publication Critical patent/RS51294B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
YUP-2005/0871A 2003-05-21 2004-05-19 Inhibitorna jedinjenja za hepatitis c RS51294B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47270903P 2003-05-21 2003-05-21
PCT/CA2004/000750 WO2004103996A1 (en) 2003-05-21 2004-05-19 Hepatitis c inhibitor compounds

Publications (2)

Publication Number Publication Date
RS20050871A RS20050871A (en) 2007-08-03
RS51294B true RS51294B (sr) 2010-12-31

Family

ID=33476973

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0871A RS51294B (sr) 2003-05-21 2004-05-19 Inhibitorna jedinjenja za hepatitis c

Country Status (33)

Country Link
US (5) US7585845B2 (US08067438-20111129-C00591.png)
EP (1) EP1654261B1 (US08067438-20111129-C00591.png)
JP (2) JP4447603B2 (US08067438-20111129-C00591.png)
KR (1) KR101115294B1 (US08067438-20111129-C00591.png)
CN (3) CN103204903A (US08067438-20111129-C00591.png)
AT (1) ATE378334T1 (US08067438-20111129-C00591.png)
AU (1) AU2004240704B9 (US08067438-20111129-C00591.png)
BR (1) BRPI0410456B8 (US08067438-20111129-C00591.png)
CA (1) CA2522577C (US08067438-20111129-C00591.png)
CL (1) CL2004001161A1 (US08067438-20111129-C00591.png)
CO (1) CO5630024A2 (US08067438-20111129-C00591.png)
CY (1) CY1107200T1 (US08067438-20111129-C00591.png)
DE (1) DE602004010137T2 (US08067438-20111129-C00591.png)
DK (1) DK1654261T3 (US08067438-20111129-C00591.png)
EA (1) EA009295B1 (US08067438-20111129-C00591.png)
EC (1) ECSP056181A (US08067438-20111129-C00591.png)
ES (1) ES2297424T3 (US08067438-20111129-C00591.png)
HR (1) HRP20080014T3 (US08067438-20111129-C00591.png)
IL (1) IL172013A (US08067438-20111129-C00591.png)
ME (1) MEP58308A (US08067438-20111129-C00591.png)
MX (1) MXPA05012545A (US08067438-20111129-C00591.png)
MY (1) MY143076A (US08067438-20111129-C00591.png)
NO (1) NO332056B1 (US08067438-20111129-C00591.png)
NZ (1) NZ544076A (US08067438-20111129-C00591.png)
PE (1) PE20050204A1 (US08067438-20111129-C00591.png)
PL (1) PL1654261T3 (US08067438-20111129-C00591.png)
PT (1) PT1654261E (US08067438-20111129-C00591.png)
RS (1) RS51294B (US08067438-20111129-C00591.png)
TW (1) TWI327145B (US08067438-20111129-C00591.png)
UA (1) UA83046C2 (US08067438-20111129-C00591.png)
UY (1) UY28323A1 (US08067438-20111129-C00591.png)
WO (1) WO2004103996A1 (US08067438-20111129-C00591.png)
ZA (1) ZA200508201B (US08067438-20111129-C00591.png)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2409985A3 (en) 1996-10-18 2013-05-01 Vertex Pharmaceuticals Incorporated Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US7119072B2 (en) * 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
UY28323A1 (es) 2003-05-21 2004-12-31 Boehringer Ingelheim Int Compuestos inhibidores de la hepatitis c
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
PE20050431A1 (es) * 2003-09-22 2005-07-19 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c
KR20060130027A (ko) * 2003-10-10 2006-12-18 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제의억제제
US7132504B2 (en) * 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2358333T3 (es) * 2004-01-21 2011-05-09 Boehringer Ingelheim International Gmbh Péptidos macrocíclicos con acción contra el virus de la hepatitis c.
WO2005073195A2 (en) 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
TWI368507B (en) 2004-02-20 2012-07-21 Boehringer Ingelheim Int Viral polymerase inhibitors
CA2556917C (en) 2004-03-15 2013-07-09 Boehringer Ingelheim International, Gmbh Process for preparing macrocyclic compounds
JP5156374B2 (ja) * 2004-05-25 2013-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 非環式ｈｃｖプロテアーゼインヒビターの調製方法
WO2006000085A1 (en) * 2004-06-28 2006-01-05 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
UY29016A1 (es) * 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
WO2006007708A1 (en) 2004-07-20 2006-01-26 Boehringer Engelheim International Gmbh Hepatitis c inhibitor peptide analogs
CN101072575A (zh) 2004-10-01 2007-11-14 威特克斯医药股份有限公司 Hcv ns3－ns4a蛋白酶抑制
MY141025A (en) 2004-10-29 2010-02-25 Vertex Pharma Dose forms
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL1863833T3 (pl) * 2005-03-08 2014-03-31 Boehringer Ingelheim Int Sposób otrzymywania związków makrocyklicznych
CA2606195C (en) 2005-05-02 2015-03-31 Merck And Co., Inc. Hcv ns3 protease inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
TWI449711B (zh) * 2005-06-30 2014-08-21 Virobay Inc Ｃ型肝炎病毒（ｈｃｖ）抑制劑
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) * 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
AR057456A1 (es) * 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
BRPI0614205A2 (pt) 2005-08-01 2016-11-22 Merck & Co Inc composto, composição farmacêutica, e, uso de composto
CN101277950B (zh) * 2005-08-02 2013-03-27 弗特克斯药品有限公司 丝氨酸蛋白酶抑制剂
US8076365B2 (en) 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2625419A1 (en) * 2005-11-03 2007-05-10 Boehringer Ingelheim International Gmbh Process for preparing substituted anisidines
US7642381B2 (en) * 2006-01-25 2010-01-05 Boehringer Ingelheim International Gmbh Two step process for preparing substituted anisidines
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CN102614490A (zh) 2006-02-27 2012-08-01 弗特克斯药品有限公司 包含vx-950的共晶体和包含所述共晶体的药物组合物
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
BRPI0714343A2 (pt) 2006-07-13 2013-03-19 Achillion Pharmaceuticals Inc peptÍdeos de 4-amino-4-oxobutanoil como inibidores de replicaÇço viral
US7718612B2 (en) * 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
CA2660555A1 (en) 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2079479B1 (en) 2006-10-24 2014-11-26 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
CA2667165A1 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
WO2008051514A2 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
KR101615500B1 (ko) * 2006-10-27 2016-04-27 머크 샤프 앤드 돔 코포레이션 Ｈｃｖ ｎｓ3 프로테아제 억제제
CA2667032A1 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008070358A2 (en) * 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2010513450A (ja) 2006-12-20 2010-04-30 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス性インドール
CA2679377A1 (en) 2007-02-26 2008-09-04 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
CA2679426A1 (en) * 2007-02-27 2008-09-04 Luc Farmer Inhibitors of serine proteases
ATE542815T1 (de) * 2007-02-27 2012-02-15 Vertex Pharma Kokristalle und pharmazeutische zusammensetzungen damit
WO2009005677A2 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
KR101596524B1 (ko) 2007-06-29 2016-02-22 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
AU2008277442A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
JP5433573B2 (ja) 2007-07-19 2014-03-05 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ 抗ウイルス剤としての大環状化合物
CA2693997C (en) 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
JP5443360B2 (ja) * 2007-08-30 2014-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド 共結晶体およびそれを含む医薬組成物
US8163693B2 (en) 2007-09-24 2012-04-24 Achillion Pharmaceuticals, Inc. Urea-containing peptides as inhibitors of viral replication
CA2708042A1 (en) * 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Quinoxalinyl derivatives
EP2224942A4 (en) 2007-12-05 2012-01-25 Enanta Pharm Inc FLUORATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
US8309685B2 (en) * 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
NZ586231A (en) * 2007-12-21 2012-12-21 Avila Therapeutics Inc HCV protease inhibitors comprising a functionalised proline derivative
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
AU2008340261C1 (en) 2007-12-21 2015-12-10 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
AU2009210789B2 (en) * 2008-02-04 2014-01-30 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8591878B2 (en) 2008-02-25 2013-11-26 Merck Sharp & Dohme Corp. Therapeutic compounds
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009241445A1 (en) 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2491090T3 (es) 2008-07-22 2014-09-05 Merck Sharp & Dohme Corp. Combinaciones de un compuesto de quinoxalina macrocíclica que es un inhibidor de la proteasa NS3 del VHC con otros agentes del VHC
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
EP2687526A1 (en) * 2008-09-16 2014-01-22 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
AU2014201788B2 (en) * 2008-09-16 2015-09-03 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
MY152824A (en) * 2008-09-17 2014-11-28 Boehringer Ingelheim Int Combination of hcv ns3 protease inhibitor with interferon and ribavirin.
JP2012502925A (ja) * 2008-09-23 2012-02-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎阻害化合物
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2738732A1 (en) * 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition of a potent hcv inhibitor for oral administration
JP5723783B2 (ja) 2008-12-10 2015-05-27 アキリオン ファーマシューティカルズ，インコーポレーテッド ウイルス複製の阻害剤としての新しい４−アミノ−４−オキソブタノイルペプチド
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20110114582A (ko) 2008-12-19 2011-10-19 길리애드 사이언시즈, 인코포레이티드 Ｈｃｖ ｎｓ３ 프로테아제 억제제
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
JP2012517478A (ja) 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤
WO2010107965A1 (en) 2009-03-19 2010-09-23 Boehringer Ingelheim International Gmbh Process for preparing sulfonyl quinolines
TR201109333T1 (tr) * 2009-03-26 2012-01-23 Daewoong Pharmaceutical Co. Ltd. Adefovir dipivoksilin yeni kristal formları ve bunların hazırlama işlemleri.
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
EP2427434B1 (en) 2009-05-05 2017-05-31 Boehringer Ingelheim International GmbH Process for preparing bromo-substituted quinolines
US8936781B2 (en) 2009-05-13 2015-01-20 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis C virus inhibitors
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
ME01718B (me) 2009-07-07 2014-09-20 Boehringer Ingelheim Int Farmaceutska kompozicija za inhibitor proteaze virusnog Hepatitis C
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US8324417B2 (en) 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
WO2011049908A2 (en) * 2009-10-19 2011-04-28 Enanta Pharmaceuticals, Inc. Bismacrokyclic compounds as hepatitis c virus inhibitors
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
CA2784646A1 (en) * 2009-12-18 2011-06-23 Boehringer Ingelheim International Gmbh Hcv combination therapy
CA2788348A1 (en) 2010-01-29 2011-08-04 Vertex Pharmaceuticals Incorporated Therapies for treating hepatitis c virus infection
US8530497B2 (en) * 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
AR082215A1 (es) 2010-07-14 2012-11-21 Vertex Pharma Composicion farmaceutica agradable al paladar
NZ608720A (en) 2010-09-21 2015-03-27 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
MX2013003060A (es) 2010-09-30 2013-05-30 Boehringer Ingelheim Int Terapia de combinacion para tratar infeccion por hcv.
EA201390532A1 (ru) * 2010-10-08 2013-09-30 Новартис Аг Композиции сульфамидых ингибиторов ns3, содержащие витамин е
US10873190B2 (en) 2010-11-19 2020-12-22 Tseng-Lu Chien Desktop or floor LED lighting device has USB-port(s)
US10873191B2 (en) 2010-11-19 2020-12-22 Tseng-Lu Chien Desk top alarm or time or LED lighting device has USB-port(s)
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2723337A1 (en) 2011-06-23 2014-04-30 Panmed Ltd. Treatment of hepatitis c virus
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2013074386A2 (en) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
CN104244926A (zh) 2012-01-12 2014-12-24 勃林格殷格翰国际有限公司 作为强效的hcv 抑制剂的稳定的药物制剂
WO2013116339A1 (en) 2012-01-31 2013-08-08 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
JP5870001B2 (ja) 2012-09-28 2016-02-24 株式会社吉野工業所 ブロー成形装置及び容器の製造方法
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
UY35212A (es) * 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
EP2970195B1 (en) 2013-03-14 2017-08-02 Achillion Pharmaceuticals, Inc. Processes for producing sovaprevir
AU2014227849A1 (en) 2013-03-15 2015-10-01 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
JP6130585B2 (ja) 2013-03-15 2017-05-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 無定形状態のｈｃｖ阻害薬の固体経口投薬製剤
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
SG11201507223TA (en) 2013-03-15 2015-10-29 Gilead Sciences Inc Macrocyclic and bicyclic inhibitors of hepatitis c virus
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
AU2015274333A1 (en) * 2014-06-12 2017-01-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Heterocyclic compounds and methods of use thereof
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN108610301B (zh) * 2016-12-12 2021-08-31 中山大学 一类手性芳杂胺类衍生物及其合成方法和应用
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US684806A (en) * 1900-03-08 1901-10-22 Filter & Brautechnische Maschinen Fabrik Akt Ges Vorm L A Enzinger Pressure-regulator for pumps.
AR205953A1 (es) * 1975-01-22 1976-06-15 Diamond Shamrock Corp Produccion de carbonatos de metales a calinos en una celula de membrana
DE3481913D1 (de) 1983-04-27 1990-05-17 Ici America Inc Prolin-derivate.
JPH01103993A (ja) 1987-10-16 1989-04-21 Sumitomo Electric Ind Ltd ダイヤモンド単結晶成長方法
JPH01135478A (ja) 1987-11-19 1989-05-29 Brother Ind Ltd 研削工具
US5164402A (en) 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
US5290405A (en) * 1991-05-24 1994-03-01 Ceramatec, Inc. NaOH production from ceramic electrolytic cell
JPH05155827A (ja) 1991-12-09 1993-06-22 Banyu Pharmaceut Co Ltd ｃｉｓ−２−アミノシクロプロパンカルボン酸誘導体の製造法
AU689589B2 (en) 1994-06-02 1998-04-02 Hoechst Marion Roussel, Inc. Novel elastase inhibitors
DE4430601A1 (de) 1994-08-22 1996-02-29 Beiersdorf Ag Zelladhäsions-Peptide zur Modifikation des Haftungsverhaltens eukaryontischer Zellen untereinander
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
DE4444893A1 (de) 1994-12-16 1996-06-20 Merck Patent Gmbh Peptide und synthetische Zellmembranen
GB9517022D0 (en) 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
DE19600034C2 (de) 1996-01-02 2003-12-24 Degussa 1,1,2-Trisubstituierte Cyclopropanverbindungen, Verfahren zu deren Herstellung und Dihydroxyethyl-substituierte 1-Amino-cyclopropan-1-carbonsäure
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
WO1997043310A1 (en) 1996-05-10 1997-11-20 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
EP2409985A3 (en) 1996-10-18 2013-05-01 Vertex Pharmaceuticals Incorporated Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
AU7127298A (en) 1997-04-14 1998-11-11 Emory University Serine protease inhibitors
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
JPH10298151A (ja) 1997-04-30 1998-11-10 Japan Energy Corp Ｃ型肝炎ウイルスプロテアーゼ阻害剤
JP2002512625A (ja) 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
JPH1135478A (ja) 1997-07-17 1999-02-09 Soyaku Gijutsu Kenkyusho:Kk キク科植物の有機抽出物を含有する抗ｃ型肝炎ウイルス剤及びプロテアーゼｎｓ３の特異的阻害剤
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
ES2234144T3 (es) 1997-08-11 2005-06-16 Boehringer Ingelheim (Canada) Ltd. Analogos de peptidos inhibidores de la hepatitis c.
ES2241157T3 (es) 1997-08-11 2005-10-16 Boehringer Ingelheim (Canada) Ltd. Peptidos inhibidores de la hepatitis c.
JPH11127861A (ja) 1997-10-29 1999-05-18 Japan Energy Corp Ｃ型肝炎ウイルス由来のセリンプロテアーゼに対する中和抗体部分ペプチド
JP3612551B2 (ja) 1997-11-07 2005-01-19 独立行政法人産業技術総合研究所 Ｃ型肝炎ウイルスのｎｓ３プロテアーゼを阻害するｒｎａ分子
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
EP1066247B1 (en) 1998-03-31 2006-11-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
JPH11292840A (ja) 1998-04-06 1999-10-26 Soyaku Gijutsu Kenkyusho:Kk ノルスタチン誘導体又はその塩
US6455571B1 (en) 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases
GB9809664D0 (en) 1998-05-06 1998-07-01 Hoffmann La Roche a-Ketoamide derivatives
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
WO2000020400A1 (en) 1998-10-05 2000-04-13 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
GB9825946D0 (en) 1998-11-26 1999-01-20 Angeletti P Ist Richerche Bio Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
AU5920400A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
EP1206449A1 (en) 1999-07-26 2002-05-22 Bristol-Myers Squibb Company Lactam inhibitors of hepatitis c virus ns3 protease
EP1206568A2 (en) 1999-08-30 2002-05-22 K.U. Leuven Research & Development Target for antiparasitic agents and inhibitors thereof
JP2001103993A (ja) 1999-10-05 2001-04-17 Japan Energy Corp 環状ペプチド及びセリンプロテアーゼ阻害剤
US6222241B1 (en) * 1999-10-29 2001-04-24 Advanced Micro Devices, Inc. Method and system for reducing ARC layer removal by providing a capping layer for the ARC layer
GB9925955D0 (en) 1999-11-02 1999-12-29 Angeletti P Ist Richerche Bio Hcv n33 protease inhibitors
CA2390349A1 (en) 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
AU2001234837A1 (en) 2000-02-08 2001-08-20 Schering Corporation Azapeptides useful in the treatment of hepatitis c
EP1261611A2 (en) 2000-02-29 2002-12-04 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
IL152022A0 (en) 2000-04-03 2003-04-10 Vertex Pharma Compounds useful as protease inhibitors and pharmaceutical compositions containing the same
KR20030036152A (ko) 2000-04-05 2003-05-09 쉐링 코포레이션 Ｎ-사이클릭 ｐ2 잔기를 포함하는 ｃ형 간염 바이러스의매크로사이클릭 ｎｓ3-세린 프로테아제 억제제
NZ521456A (en) 2000-04-19 2004-07-30 Schering Corp Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
WO2002008251A2 (en) 2000-07-21 2002-01-31 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
HUP0303358A3 (en) 2000-07-21 2005-10-28 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
DK1385870T3 (da) 2000-07-21 2010-07-05 Schering Corp Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
EP1337550B1 (en) 2000-11-20 2006-05-24 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2474156C (en) 2002-02-01 2011-09-20 Boehringer Ingelheim International Gmbh Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of ns3 (hepatitis c)
US6642204B2 (en) * 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
AU2003299519A1 (en) 2002-05-20 2004-05-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
AU2003301959A1 (en) 2002-05-20 2004-06-03 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
WO2003099316A1 (en) 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
WO2004101605A1 (en) * 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
ATE486889T1 (de) 2003-03-05 2010-11-15 Boehringer Ingelheim Int Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
UY28323A1 (es) * 2003-05-21 2004-12-31 Boehringer Ingelheim Int Compuestos inhibidores de la hepatitis c
PE20050431A1 (es) 2003-09-22 2005-07-19 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1702089A2 (en) * 2003-12-11 2006-09-20 American Pacific Corporation Electrolytic method to make alkali alcoholates using ceramic ion conducting solid membranes
WO2005073195A2 (en) * 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
JP5156374B2 (ja) 2004-05-25 2013-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 非環式ｈｃｖプロテアーゼインヒビターの調製方法
RU2004119195A (ru) 2004-06-24 2005-12-10 Дмитрий Александрович Гертнер (RU) Способ бесконтактной, гарантированной доставки товаров до конечного потребителя и система для его реализации
WO2006000085A1 (en) 2004-06-28 2006-01-05 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
WO2006007708A1 (en) 2004-07-20 2006-01-26 Boehringer Engelheim International Gmbh Hepatitis c inhibitor peptide analogs
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
WO2008124047A1 (en) * 2007-04-03 2008-10-16 Ceramatec, Inc. Electrochemical process to recycle aqueous alkali chemicals using ceramic ion conducting solid membranes
US20090090638A1 (en) * 2007-10-05 2009-04-09 Kelly Michael T Processes and reactors for alkali metal production
US8246863B2 (en) * 2009-06-26 2012-08-21 Ceramatec, Inc. Alkali metal super ionic conducting ceramic

Also Published As

Publication number Publication date
UY28323A1 (es) 2004-12-31
AU2004240704B9 (en) 2009-10-22
CN103204903A (zh) 2013-07-17
RS20050871A (en) 2007-08-03
ECSP056181A (es) 2006-04-19
MXPA05012545A (es) 2006-02-08
CO5630024A2 (es) 2006-04-28
TW200508220A (en) 2005-03-01
EA009295B1 (ru) 2007-12-28
DE602004010137D1 (de) 2007-12-27
EP1654261A1 (en) 2006-05-10
AU2004240704A1 (en) 2004-12-02
EP1654261B1 (en) 2007-11-14
EA200501689A1 (ru) 2006-06-30
BRPI0410456B1 (pt) 2019-07-09
CN1791599A (zh) 2006-06-21
HRP20080014T3 (en) 2008-02-29
ZA200508201B (en) 2007-02-28
DK1654261T3 (da) 2008-01-14
US8067438B2 (en) 2011-11-29
CA2522577A1 (en) 2004-12-02
CN103203010A (zh) 2013-07-17
US20120269769A1 (en) 2012-10-25
BRPI0410456B8 (pt) 2021-05-25
ME00382B (me) 2011-05-10
UA83046C2 (ru) 2008-06-10
IL172013A (en) 2011-10-31
BRPI0410456A (pt) 2006-06-06
US7939667B2 (en) 2011-05-10
JP4447603B2 (ja) 2010-04-07
DE602004010137T2 (de) 2008-09-11
ES2297424T3 (es) 2008-05-01
KR101115294B1 (ko) 2012-04-12
US20070243166A1 (en) 2007-10-18
AU2004240704B2 (en) 2009-08-20
JP2006528937A (ja) 2006-12-28
PE20050204A1 (es) 2005-05-04
US20110177030A1 (en) 2011-07-21
US20120034187A1 (en) 2012-02-09
PL1654261T3 (pl) 2008-04-30
NO20056047L (no) 2006-01-31
TWI327145B (en) 2010-07-11
US7585845B2 (en) 2009-09-08
WO2004103996A1 (en) 2004-12-02
MY143076A (en) 2011-02-28
NO332056B1 (no) 2012-06-11
CY1107200T1 (el) 2012-11-21
US20050020503A1 (en) 2005-01-27
CL2004001161A1 (es) 2005-04-08
ATE378334T1 (de) 2007-11-15
NZ544076A (en) 2009-04-30
MEP58308A (en) 2011-05-10
KR20060013671A (ko) 2006-02-13
JP2010043129A (ja) 2010-02-25
CA2522577C (en) 2011-04-26
PT1654261E (pt) 2008-01-18

Similar Documents

Publication Publication Date Title
TW200508220A (en) Hepatitis C inhibitor compounds
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
WO2004101602A3 (en) Hepatitis c inhibitor peptide analogs
RS20060197A (en) Macrocyclic peptides active against the hepatitis c virus
SG164376A1 (en) Hcv ns3 protease inhibitors
IL152022A0 (en) Compounds useful as protease inhibitors and pharmaceutical compositions containing the same
MY140680A (en) Hepatitis c virus inhibitors
MY164469A (en) Hcv ns3 protease inhibitors
MX2009008872A (es) Compuestos macrociclicos como inhibidores de proteasa ns3 del virus de hepatitis c.
WO2004014852A3 (en) Iminothiazolidinones as inhibitors of hcv replication
ATE542826T1 (de) Inhibitoren des hepatitis-c-virus
WO2006119061A3 (en) Hcv ns3 protease inhibitors
UA90909C2 (en) Hcv ns3 protease inhibitors
WO2003051910A3 (en) Inhibitors of hepatitis c virus protease